Clinical Report: This Week’s CGT News: Antifreeze Sugars Protect CAR T Cells

Background

The approval of GENGLYCOS marks a milestone in the treatment of glycogen storage disease type Ia. Additionally, advancements in CAR T cell therapies, particularly in solid tumors, are ongoing efforts to enhance the effectiveness of immunotherapies.

Data Highlights

Key Findings

• GENGLYCOS received FDA accelerated approval for GSDIa, reducing cornstarch intake.
• In a Phase III trial, GENGLYCOS significantly decreased cornstarch requirements after 48 weeks.
• New freezing methods using trehalose and sucrose improved CAR T cell viability post-thaw.
• Focused ultrasound can enhance CAR T cell targeting in solid tumors by temporarily displaying CD19 on cancer cells.
• A novel lipid nanoparticle increased mRNA activity significantly, showing potential for various therapeutic applications.
• Red blood cell-derived carriers may improve gene therapy delivery by evading immune responses.

Clinical Implications

The approval of GENGLYCOS provides a new treatment option for patients with GSDIa, emphasizing the importance of monitoring cornstarch intake. The advancements in CAR T cell preservation and targeting techniques may facilitate broader access to these therapies.

Conclusion

Recent developments in gene therapy and CAR T cell technology represent progress in treating complex diseases.

Related Resources & Content

1. FDA, FDA, 2026 -- FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia
2. the medicine maker, This Week’s CGT News: Radiopharmaceutical Boosts CAR T, 2026
3. the medicine maker, This Week’s CGT News: CAR-T Breaks New Ground in Alzheimer’s, 2026
4. the medicine maker, This Week’s CGT News: Genentech Terminates Adaptive Biotechnologies Collaboration, 2025
5. Safety and Efficacy of DTX401, an AAV8-Mediated Liver-Directed Gene Therapy, in Adults With Glycogen Storage Disease Type I a (GSDIa) - PubMed
6. the medicine maker — This Week’s CGT News: Promising Data for In Vivo CAR T
7. Cell-preservation technique could make CAR-T cell therapy more accessible
8. Impact of cryopreservation on PBMC-derived CAR-T cell manufacturing outcomes: a systematic review
9. FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia | FDA
10. https://www.fda.gov/media/194364/download?attachment=
11. Safety and Efficacy of DTX401, an AAV8-Mediated Liver-Directed Gene Therapy, in Adults With Glycogen Storage Disease Type I a (GSDIa) - PubMed
12. Person-centered outcomes for liver glycogen storage diseases: Development of an international consensus-based standard outcome set - ScienceDirect
13. Glucose-Enhanced Cryopreservation of hCAR-T Cells: Improved Recovery and Reduced Apoptosis - PubMed